A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Documenti analoghi

• Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants
  di: Ofer Michael Gonen, et al.
  Pubblicazione: (2025)
• First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
  di: Hidetoshi Shimizu, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
  di: Akira Tanaka, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  di: Kyoko Miyamoto, et al.
  Pubblicazione: (2024)
• A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
  di: Xiaomeng Mao, et al.
  Pubblicazione: (2024)